Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: Not as bad as their reputation

Journal of Virology

Volumn 87, Issue 11, 2013, Pages 6283-6295

  Steffensen, Maria Abildgaard ^a   Holst, Peter Johannes ^a   Steengaard, Sanne Skovvang ^a   Jensen, Benjamin Anderschou Holbech ^a   Bartholdy, Christina ^a   Stryhn, Anette ^a   Christensen, Jan Pravsgaard ^a   Thomsen, Allan Randrup ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD27 ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GP 33; GLYCOPROTEIN GP 34; INTERLEUKIN 7 RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY G MEMBER 1; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA DETERMINATION; EXPERIMENTAL MOUSE; EXPRESSION VECTOR; FEMALE; GENE GUN IMMUNIZATION; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; VACCINATION; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84878188022     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00465-13     Document Type: Article

References (48)

1. Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, Johnston RE, Liao HX, Kepler TB, Haynes BF, Ramsburg E. 2008. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26:6108-6118.
2. Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, Giles-Davis W, Wilson JM, Ertl HC. 2003. A simian replication- defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170:1416-1422.
3. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP. 2008. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J. Immunol. 180:3339-3346.
4. + T cells: implications for their use as vaccines. Blood 110:1916-1923.
5. + T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J. Immunol. 176:200-210.
6. Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, Iampietro MJ, Barouch DH. 2013. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J. Virol. 87:1373-1384.
7. + T cells induced by different adenovirus vectors. J. Virol. 87:1359-1372.
8. + T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J. Immunol. 184:4431-4439.
9. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
10. Masopust D, Ha SJ, Vezys V, Ahmed R. 2006. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J. Immunol. 177:831-839.
11. Nolz JC, Harty JT. 2011. Protective capacity of memory CD8(+) T cells is dictated by antigen exposure history and nature of the infection. Immunity 34:781-793.
12. West EE, Youngblood B, Tan WG, Jin HT, Araki K, Alexe G, Konieczny BT, Calpe S, Freeman GJ, Terhorst C, Haining WN, Ahmed R. 2011. Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity 35:285-298.
13. Jabbari A, Harty JT. 2006. Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype. J. Exp. Med. 203:919-932.
14. Wirth TC, Xue HH, Rai D, Sabel JT, Bair T, Harty JT, Badovinac VP. 2010. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity 33:128-140.
15. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, Newgard CB. 1994. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43(Pt A):161-189.
16. Mizuguchi H, Kay MA. 1998. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9:2577-2583.
17. Mizuguchi H, Kay MA. 1999. A simple method for constructing E1-and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 10: 2013-2017.
18. + T cells in gene gun DNA-vaccinated mice. Eur. J. Immunol. 33:1941-1948.
19. + T cell responses with an adenoviral vectorbased hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J. Immunol. 186:2355-2364.
20. Steffensen MA, Jensen BA, Holst PJ, Bassi MR, Christensen JP, Thomsen AR. 2012. Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses. PLoS One 7:e34884. doi:10.1371/journal.pone.0034884.
21. Thomsen AR, Johansen J, Marker O, Christensen JP. 1996. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice. J. Immunol. 157:3074-3080.
22. Battegay M, Cooper S, Althage A, Banziger J, Hengartner H, Zinkernagel RM. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24-or 96-well plates. J. Virol. Methods 33:191-198.
23. Leisner C, Loeth N, Lamberth K, Justesen S, Sylvester-Hvid C, Schmidt EG, Claesson M, Buus S, Stryhn A. 2008. One-pot, mix-and-read peptide-MHC tetramers. PLoS One 3:e1678. doi:10.1371/journal.pone .0001678.
24. + T cells and their conversion to memory T cells. Immunol. Rev. 236:151-166.
25. + T cells are generated after lymphocytic choriomeningitis virus and influenza virus infections. J. Immunol. 185:2182-2190.
26. + T cells during an acute virus infection. Immunity 8:167-175.
27. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-187.
28. Kristensen NN, Madsen AN, Thomsen AR, Christensen JP. 2004. Cytokine production by virus-specific CD8(+) T cells varies with activation state and localization, but not with TCR avidity. J. Gen. Virol. 85: 1703-1712.
29. Masopust D, Jiang J, Shen H, Lefrancois L. 2001. Direct analysis of the dynamics of the intestinal mucosa CD8 T cell response to systemic virus infection. J. Immunol. 166:2348-2356.
30. + T cells during viral infection: correlation with stable memory development. J. Gen. Virol. 83:2123-2133.
31. Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR. 2009. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cellindependent CD8(+) T-cell-mediated tumor control. Eur. J. Immunol. 39:2725-2736.
32. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10:29-37.
33. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A. 2012. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4:115ra2. doi:10.1126/scitranslmed.3002925.
34. Tsujimura A, Shida K, Kitamura M, Nomura M, Takeda J, Tanaka H, Matsumoto M, Matsumiya K, Okuyama A, Nishimune Y, Okabe M, Seya T. 1998. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem. J. 330(Pt 1):163-168.
35. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297.
36. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH. 2005. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J. Virol. 79:9694-9701.
37. Thorner AR, Lemckert AA, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga MJ, Barouch DH. 2006. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol. 80: 12009-12016.
38. Vogels R, Zuijdgeest D, van, Hartkoorn RRE, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van, Quax MMP, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77:8263-8271.
39. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:379-385.
40. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211:236-254.
41. Wiesel M, Walton S, Richter K, Oxenius A. 2009. Virus-specific CD8 T cells: activation, differentiation and memory formation. APMIS 117:356-381.
42. Holst PJ, Bartholdy C, Stryhn A, Thomsen AR, Christensen JP. 2007. Rapid and sustained CD4(+) T-cell-independent immunity from adenovirus-encoded vaccine antigens. J. Gen. Virol. 88:1708-1716.
43. + T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. Blood 117: 1146-1155.
44. + T-cell expansion and maintenance following immunization with recombinant adenovirus. J. Virol. 83:12027-12036.
45. + T lymphocytes during active, latent, and resolved infection and its relation with CD57. J. Immunol. 174:6088-6094.
46. Cush SS, Flano E. 2011. KLRG1+NKG2A+ CD8 T cells mediate protection and participate in memory responses during gamma-herpesvirus infection. J. Immunol. 186:4051-4058.
47. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M, Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15: 293-299.
48. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Jr, Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527.